AbstractBackgroundCurrent guidelines recommend androgen deprivation therapy only for men with very high-risk prostate cancer (PCa), but there is little evidence to support this stance.ObjectiveTo investigate the association between radical local treatment and mortality in men with very high-risk PCa.Design, setting, and participantsSemiecologic study of men aged <80 yr within the Prostate Cancer data Base Sweden, diagnosed in 1998–2012 with very high-risk PCa (local clinical stage T4 and/or prostate-specific antigen [PSA] level 50–200ng/ml, any N, and M0). Men with locally advanced PCa (local clinical stage T3 and PSA level <50ng/ml, any N, and M0) were used as positive controls.InterventionProportion of men who received prostatectomy or fu...
BACKGROUND The value of radical prostatectomy (RP) as an approach for very high-risk prostate can...
Background Androgen suppression therapy and radiotherapy are used to treat locally advanced prostate...
OBJECTIVE: To detail the distribution of causes of death from localized prostate cancer (PCa). PATIE...
Background: Current guidelines recommend androgen deprivation therapy only for men with very high-ri...
AbstractBackgroundCurrent guidelines recommend androgen deprivation therapy only for men with very h...
Objective To evaluate whether the effects of radical treatment in men with locally advanced prostate...
Background: There are limited prognostic data for locally advanced prostate cancer PCa to guide in t...
BACKGROUND: There is no consensus on the optimal treatment for localized high-risk prostate cancer (...
Background Observational data has indicated improved survival after radical prostatectomy (RP) comp...
Study Type - Prognosis inception (cohort) Level of Evidence 2 What's known on the subject? and What ...
Objective The optimal primary treatment for clinically high-risk prostate cancer (PCa) is controvers...
INTRODUCTION & OBJECTIVES: The optimal primary treatment for men with clinically high-risk prostate ...
Tailored treatment with adequate timing is essential for the quality of prostate cancer care at all ...
Background: There are no conclusive results from randomized trials on radiotherapy (RT) versus radic...
Background and Objective Changes in diagnostic work-up, histopathological assessment, and treatment ...
BACKGROUND The value of radical prostatectomy (RP) as an approach for very high-risk prostate can...
Background Androgen suppression therapy and radiotherapy are used to treat locally advanced prostate...
OBJECTIVE: To detail the distribution of causes of death from localized prostate cancer (PCa). PATIE...
Background: Current guidelines recommend androgen deprivation therapy only for men with very high-ri...
AbstractBackgroundCurrent guidelines recommend androgen deprivation therapy only for men with very h...
Objective To evaluate whether the effects of radical treatment in men with locally advanced prostate...
Background: There are limited prognostic data for locally advanced prostate cancer PCa to guide in t...
BACKGROUND: There is no consensus on the optimal treatment for localized high-risk prostate cancer (...
Background Observational data has indicated improved survival after radical prostatectomy (RP) comp...
Study Type - Prognosis inception (cohort) Level of Evidence 2 What's known on the subject? and What ...
Objective The optimal primary treatment for clinically high-risk prostate cancer (PCa) is controvers...
INTRODUCTION & OBJECTIVES: The optimal primary treatment for men with clinically high-risk prostate ...
Tailored treatment with adequate timing is essential for the quality of prostate cancer care at all ...
Background: There are no conclusive results from randomized trials on radiotherapy (RT) versus radic...
Background and Objective Changes in diagnostic work-up, histopathological assessment, and treatment ...
BACKGROUND The value of radical prostatectomy (RP) as an approach for very high-risk prostate can...
Background Androgen suppression therapy and radiotherapy are used to treat locally advanced prostate...
OBJECTIVE: To detail the distribution of causes of death from localized prostate cancer (PCa). PATIE...